Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Patients diagnosed with Neuroendocrine Tumors (NET) often are also diagnosed with Neuroendocrine Liver Metastases (NLM) during the course of their disease. NLM can cause significant morbidity and mortality, oftentimes much more than compared to patients with NET. Treatment options have been limited in the past, focusing on surgical resections, for which only a minority of patients are candidates. However, developments of new treatment modalities have progressed rapidly and patients with NLM now have significantly more options, including surgical-directed therapies; liver-directed therapies; and nonsurgical, non-liver-directed therapies. This review provides information about the roles of hepatic resection, orthotopic liver resection, radiofrequency ablation, hepatic artery embolization and hepatic artery chemoembolization, hepatic artery radioembolization and selective internal radiation therapy, peptide receptor radionuclide therapy, systemic chemotherapy, biotherapies including somatostatin analogs and interferon-α, vascular endothelial growth factor and mTOR targets, and microRNA-regulated pathways. Given these new options, the clinician can tailor therapy specific to the patient diagnosed with NLM, thereby giving the patient the best possible chance of prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“The more the tumor expresses somatostatin receptors as compared to the surrounding tissue, the more effective the PRRT will be.”
BackgroundRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456 · cited 1×
“In one study with 310 patients, median overall survival rate from initiation of PRRT was 46 months [47].”
BackgroundDisrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Mayr, C., Hemann, M. T., & Bartel, D. P. (2007) · Science · doi:10.1126/science.1137999 · Cited by 1,100
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849 · cited 2×
“to a longer half-life of approximately two hours [61].”
BackgroundMoertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840 · cited 1×
“…fewer nodular liver metastatic lesions, local resection or thermal ablation is recommended; for a higher-tumor load due to unresectable multinodular disease or recurrent disease after resection, hepatic artery embolization, hepatic artery chemoembolization, or radioembolization is warranted [19].”
BackgroundMicroRNA expression and function in cancer
Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A., & Croce, C. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.006 · Cited by 780 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundStrosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011) · Cancer · doi:10.1002/cncr.25425 · Cited by 766 · cited 1×
“temozolomide and thalidomide showed a response rate of 45% [52], and a retrospective study of temozolomide and capecitabine showed a response rate of 70%, a median PFS of 18 months, and an overall 2-year survival of 92% [53].”
Background
Research works printed but not linked: 21
- 2009, 96, 175
- 1990, 108, 1091
- 1998, 66, 1307
- 2002, 73, 386
- 1996, 62, 724
- 2007, 26, 861
- 2011, 18, 127
- 1999, 81, 1351
- 1985, 253, 2741
- 1986, 315, 663
- 1998, 77, 632
- 1991, 30, 503
- 1993, 72, 244
- 1993, 32, 225
- 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0
- 1991, 23, 2197
- 2009, 31, 169
- 1990, 26, 62
- 2000, 118, 735
- 1999, 84, 3336
- 1996, 57, 84
Cited by
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
“Another option with neuroendocrine liver lesions, given that the majority of them are hypervascular, is hepatic directed procedures, which include ablative therapy, transarterial embolization, transarterial chemoembolization, and selective internal radiation therapy with yttrium-90 microspheres.(117) Systemic, i.”
BackgroundIto, T., Igarashi, H., Uehara, H., Berna, M. J., & Jensen, R. T. (2013) · Medicine · doi:10.1097/md.0b013e3182954af1 · Cited by 217
Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management
Sahani, D. V., Bonaffini, P. A., Fernández–Del Castillo, C., & Blake, M. A. (2013) · Radiology · doi:10.1148/radiol.12112512 · Cited by 191
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
BackgroundTherapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances
Ito, T., Igarashi, H., & Jensen, R. T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0642-8 · Cited by 124
“debulking surgery is not recommended where resection cannot be complete or cannot result in the removal of [90 % of the metastatic tumor, because studies show this does not result in improved survival compared with that in patients who do not undergo debulking surgery [21, 25, 26, 98, 101, 102].”
Influential
Metadata
- Authors
- Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- O'Mahony, Christine A.
- Venue
- International Journal of Hepatology
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 2090-3448 (ISSN-L)
- 2090-3456
- PMC
- PMC3195553
- OpenAlex
- W2108019032
- Cited by
- 69
- References
- 103
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 6 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Hepatology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- neuroendocrine liver metastases, neuroendocrine tumors, hepatectomy, orthotopic liver transplantation, radiofrequency ablation, hepatic artery embolization, hepatic artery chemoembolization, radioembolization, peptide receptor radionuclide therapy, somatostatin analogues, interferon-alpha, mTOR inhibitors, vascular endothelial growth factor, microRNA, systemic chemotherapy, biologic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review. https://app.cochat.ai/papers/10.4061/2011/154541
- The paper
- Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011). Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review. International Journal of Hepatology. https://doi.org/10.4061/2011/154541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
